Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $68.4 million.

  • Century Therapeutics' Total Liabilities fell 6456.3% to $68.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.4 million, marking a year-over-year decrease of 6456.3%. This contributed to the annual value of $191.9 million for FY2024, which is 904.45% up from last year.
  • Latest data reveals that Century Therapeutics reported Total Liabilities of $68.4 million as of Q3 2025, which was down 6456.3% from $74.8 million recorded in Q2 2025.
  • In the past 5 years, Century Therapeutics' Total Liabilities ranged from a high of $194.3 million in Q2 2024 and a low of $68.4 million during Q3 2025
  • For the 4-year period, Century Therapeutics' Total Liabilities averaged around $158.3 million, with its median value being $175.9 million (2023).
  • As far as peak fluctuations go, Century Therapeutics' Total Liabilities soared by 1459.66% in 2024, and later plummeted by 6456.3% in 2025.
  • Over the past 4 years, Century Therapeutics' Total Liabilities (Quarter) stood at $183.8 million in 2022, then decreased by 4.28% to $175.9 million in 2023, then grew by 9.04% to $191.9 million in 2024, then crashed by 64.36% to $68.4 million in 2025.
  • Its Total Liabilities was $68.4 million in Q3 2025, compared to $74.8 million in Q2 2025 and $75.2 million in Q1 2025.